Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CPX-351 Approved in Europe for 2 AML Types

August 27th 2018

The European Commission has approved CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, for adult patients with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia

August 27th 2018

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Dr. Hobbs Discusses the Treatment Landscape of CML

August 24th 2018

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the treatment landscape of chronic myeloid leukemia.

Ansell Addresses Immune Evasion in Hodgkin Lymphoma

August 24th 2018

Stephen M. Ansell, MD, PhD, discusses overcoming immune evasion in lymphoma.

Expert Highlights Potential of Zanubrutinib in Waldenstrom Macroglobulinemia

August 24th 2018

Judith Trotman, MBChB, FRACP, FRCPA, discusses zanubrutinib’s effect on patient quality of life and how the BTK inhibitor can be used to extend survival for younger patients with WM.

Dr. Jabbour Discusses Recent Advancements in ALL

August 23rd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.

Dr. Ansell Discusses the Role of PD-1 Blockade in Lymphoma

August 20th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Dr. Smith Discusses the Diagnosis of Double-Hit Lymphoma

August 17th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the diagnosis of double-hit lymphoma.

SL-401 Emerging as First Targeted Therapy for Rare Blood Cancer

August 16th 2018

Naveen Pemmaraju, MD, discusses SL-401 and the future of treatment for patients with blastic plasmacytoid dendritic cell neoplasm.

Unmet Needs and Future Directions in CML

August 16th 2018

TFR With Nilotinib in CML: ENESTfreedom and ENESTop

August 16th 2018

Chronic Myeloid Leukemia: Selecting Patients for TFR

August 16th 2018

Achieving Treatment-Free Remissions in CML

August 16th 2018

CML: Improving Treatment for Patients Who Don't Respond

August 16th 2018

Chronic Myeloid Leukemia: Understanding Loss of Response

August 16th 2018

Optimizing the Use of BCR-ABL TKIs in CML

August 16th 2018

CML: Considering Second-Generation TKIs

August 16th 2018

TIDEL-II: Switching From Imatinib to Nilotinib in CML

August 16th 2018

When to Switch Therapy in Chronic Myeloid Leukemia

August 16th 2018

CML: Factors in Selecting a BCR-ABL TKI

August 16th 2018